A randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial to assess the safety and efficacy of ciclesonide, applied as a nasal spray (200microg once daily) in the treatment of seasonal allergic rhinitis (SAR) in patients 12 years and older.

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial to assess the safety and efficacy of ciclesonide, applied as a nasal spray (200microg once daily) in the treatment of seasonal allergic rhinitis (SAR) in patients 12 years and older.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors ALTANA Pharma; AstraZeneca
  • Most Recent Events

    • 09 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top